Accumulating evidence suggests that bisphenol A (BPA) exposure is associated with nonalcoholic fatty liver disease. Disruption of autophagy causes lipid accumulation in hepatocytes. Whether and how BPA regulates autophagy remains to be explored. We investigated the effect of BPA on autophagy in hepatocytes and examined the influence of BPA-regulated autophagy on hepatic lipid accumulation. Male CD1 mice were treated with BPA for 8 weeks, followed by histological and biochemical evaluation of liver lipids and autophagy. Also, the effects of BPA on autophagy and hepatic lipid accumulation were examined in primary hepatocytes and HepG2 cells. Lipid content in HepG2 cells and/or primary hepatocytes was increased obviously after BPA exposure. In addition, BPA exposure caused accumulation of autophagosomes in HepG2 cells and enhanced colocalization of Bodipy 493/503 with microtubule associated protein light-chain 3. These changes were accompanied with increased expression levels of p-mammalian target of rapamycin, p-p70S6 kinase, p-ULK1 and decreased expression levels of Atg5. BPA exposure also downregulated the expression of cathepsin L and decreased cytoplasmic retention of acridine orange in HepG2 cells. The impaired autophagic degradation was further evidenced by increased levels of p62 in BPA-treated HepG2 cells. At the whole animal level, BPA treatment induced lipid accumulation in livers of male CD1 mice, which was accompanied with changes in hepatic autophagy-related proteins. Moreover, induction of autophagy by Torin1 protected against BPA-induced lipid accumulation whereas suppression of autophagy by chloroquine exacerbated BPA-induced lipid accumulation in HepG2 cells. BPA dysregulates autophagy in hepatocytes, which is linked to BPA-induced hepatic lipid accumulation. (Endocrinology 158: 2799(Endocrinology 158: -2812(Endocrinology 158: , 2017 B isphenol A (BPA) is a plasticizer that has been used for many years in the manufacture of polycarbonate and epoxy resins. Much evidence demonstrates that BPA is a highly prevalent endocrine disruptor present in our environment. Under certain conditions (e.g., sterilization, altered pH, and increased temperature), BPA can be released and contaminate the food chain, leading to a daily exposure in consumers (1). Epidemiological studies have showed an association between urinary levels of BPA and the prevalence of diabetes, cardiovascular diseases, and elevated markers of liver toxicity (2-4). Also, the link between BPA and hepatic lipid deposition has been indicated by a number of studies. However, the mechanisms underlying the role for BPA in hepatic lipid deposition remain to be elucidated (5-7).
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isphenol A (BPA) is a plasticizer that has been used for many years in the manufacture of polycarbonate and epoxy resins. Much evidence demonstrates that BPA is a highly prevalent endocrine disruptor present in our environment. Under certain conditions (e.g., sterilization, altered pH, and increased temperature), BPA can be released and contaminate the food chain, leading to a daily exposure in consumers (1) . Epidemiological studies have showed an association between urinary levels of BPA and the prevalence of diabetes, cardiovascular diseases, and elevated markers of liver toxicity (2) (3) (4) . Also, the link between BPA and hepatic lipid deposition has been indicated by a number of studies. However, the mechanisms underlying the role for BPA in hepatic lipid deposition remain to be elucidated (5) (6) (7) .
Autophagy is a cellular progress of the turnover of organelles, proteins, and other macromolecules involving the lysosomal degradation pathway. Disruption of autophagy is associated with many metabolic disorders, including diabetes, obesity, liver injuries, and nonalcoholic fatty liver disease (8) (9) (10) . A recent study identified a critical function for autophagy in lipid metabolism, which is termed lipophagy. Of importance, inhibition of lipophagy caused enhancement of triglyceride (TG) storage in hepatocytes and in mouse livers (11) . The lipophagic process involves the sequestration of lipid droplet in double-membrane autophagosomes, a process that embodies lipidation of microtubule associated protein light-chain 3 (LC3). The autophagosomes then fuse with lysosomes to form autolysosomes and there is subsequent degradation of the lipid droplet by lysosomal enzymes within the autolysosomes (12) .
As autophagy plays a crucial role in lipid metabolism, we reckon that dysregulation of autophagy contributes to BPAinduced lipid accumulation. In the current study, we investigated the effect of BPA on autophagy in hepatocytes and examined the influence of BPA-regulated autophagy on hepatic lipid accumulation. Our study revealed that BPA had important impacts on autophagy. Specifically, BPA not only inhibited autophagic induction but also impaired autophagic degradation. The imbalance between suppressed autophagic induction and reduced autophagic degradation resulted in the accumulation of autophagosomes. Moreover, induction of autophagy protected against BPA-induced lipid accumulation whereas suppression of autophagy exacerbated BPA-induced lipid accumulation, demonstrating that dysregulated autophagy in hepatocytes promotes BPA-induced hepatic lipid accumulation.
Materials and Methods

Chemical reagents
BPA, bovine serum albumin (BSA), oleic acid, palmitic acid, chloroquine (CQ), pepstatin A, E64D, and NH 4 Cl were purchased from Sigma-Aldrich (St. Louis, MO). Torin1 was purchased from Bio-Techne (Minneapolis, MN). Culture media, serum, and Bodipy 493/503 were purchased from Invitrogen (Carlsbad, CA). The following antibodies were used: anti-LC3 (Sigma-Aldrich), anti-mammalian target of rapamycin (anti-mTOR; Millipore, Billerica, MA), anti-phospho-mTOR (Abcam, Cambridge, United Kingdom), anti-p70s6k (Cell Signaling Technologies, Danvers, MA), anti-phospho-p70s6k (Cell Signaling Technologies), anti-SQSTM1/p62 (Bioss), antiAtg5 (Bioss, Beijing, China), anti-cathepsin L (Abcam), antiphospho-ULK1 (Cell Signaling Technologies), FITC-labeled goat anti-rabbit IgG (Beyotime, Shanghai, China), and Cy3-labeled goat anti-rabbit IgG (Beyotime).
Cell culture
HepG2 cells were cultured in modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 50 mM sodium pyruvate, 1 g/L glucose, 100 UI/mL penicillin, 0.1 mg/mL streptomycin, and maintained in a humidified atmosphere 5% CO 2 and 95% air at 37°C. To examine the effect of BPA, cells were incubated in medium supplemented with 2% BSA without FBS in the presence of BPA for 24 hours at a concentration of 0.001, 0.1, 1, 4, or 10 mM. Some cells were treated with an oleic acid (OA) and palmitic acid (PA) combination (OA/PA = 2:10) at a final concentration 0.75 mM as positive control. The BPAcontaining medium was composed of DMEM without phenol red and serum to avoid estrogen contamination. In the study using autophagy inhibitors, HepG2 cells were pretreated with or without EE (a combination of 10 mg/mL E64d, 10 mg/mL pepstatin A, and 20 mM NH 4 Cl) or CQ at a concentration of 20 mM prior to BPA (10 mM) exposure. In the study using an autophagy inducer, HepG2 cells were pretreated with or without Torin1 at a concentration of 10 mM prior to BPA (10 mM) exposure.
Isolation and culture of primary mouse hepatocytes
Primary hepatocytes were prepared from male C57BL/6J mice using the two-step collagenase perfusion method (13) . Subsequently, the hepatocytes were suspended in the DMEM-F12 supplemented with 10% FBS and 100 UI/mL penicillin and 0.1 mg/mL streptomycin. Cell viability was assayed with trypan blue staining. The cells with a viability greater than 80% were seeded into six-well plates coated with rat-tail collagen and maintained at 37°C in 5% CO 2 for 4 hours to allow attachment. After washing with phosphate-buffered saline (PBS), the adherent hepatocytes were incubated with FBS-free DMEM-F12 medium supplemented with 0.1 mM dexamethasone and 5 ng/mL epidermal growth factor for an additional 24 hours before further treatment. For BPA treatment, the cells were further cultured media supplemented with BPA for another 24-hour period. All procedures involving laboratory animals have been previously approved by the Institutional Animal Care and Use Committee of Chongqing Medical University.
Animals
All animals received human care and experimental procedures were conducted with the approval by Animal Care Committee of Chongqing Medical University and were in compliance with the NIH Guidelines on the Care and Use of Laboratory Animals. Sixweek-old male CD1 mice were purchased from Charles River Laboratory and randomly divided into four groups (n = 12/group) to receive a standard diet or diets containing different concentrations of BPA for 8 weeks. Briefly, mice were exposed to oral BPA at various concentrations at 0 (controls), 5, 50, and/or 500 mg/kg/d. At the end of BPA exposure, blood samples were collected for TG assays. To collect liver samples, CD1 mice were anesthetized after lavaging with phosphate buffer through inferior vena cava to remove the liver blood. Thereafter, the livers of CD1 mice were dissected and fixed in 4% paraformaldehyde at 4°C, dehydrated through 30% sucrose. The fixed livers were embedded with optimum cutting temperature compound and then stored at -80°C. For further analysis, 8-mm liver sections were used subjected to Oil Red O staining and/or immunohistochemistry.
Oil Red O staining
Lipid accumulation in HepG2 and primary hepatocytes, as well as livers of CD1 mice, was evaluated using Oil Red O staining. Briefly, the treated cells and/or the liver sections prepared as described previously were washed three times in PBS, stained with filtered Oil Red O (in 60% isopropanol) for 30 minutes at room temperature, and counterstained with hematoxylin for 2 minutes. After glycerol gelatin sealing glasses, the stained cells and/or liver sections were analyzed using light microscopy (Leica Camera, Wetzlar, Germany).
Oil Red O staining-based semiquantification
To quantify lipid accumulation, 100% isopropyl was added to each well of a 24-well plate where cells were stained for Oil Red O. The dye stained was extracted and removed immediately and subjected to determination of the absorbance at 510 nm using spectrophotometer.
Quantitative measurement of intracellular TG
After harvest of the treated hepatocytes, TGs were extracted using solvents (hexane/isopropanol = 2/3.5 volume-to-volume ratio). The lipid phase was collected, dried in vacuum, and redissolved using the aforementioned solvents. The proteins were redissolved with NaOH (1 mmol/L) and subjected to a Lowry kit (Shenggong, Shanghai, China) to measure protein concentrations. The concentrations of TG were analyzed using commercial kits (Dongou, Zhejiang, China) and normalized using the total amount of protein.
Immunofluorescence microscopy
HepG2 cells and primary hepatocytes were grown on glass coverslips and incubated with media supplemented with OA and PA mixture or different concentrations of BPA (as described previously) for 24 hours. After incubation, the treated cells as well as liver sections prepared previously were fixed in 4% paraformaldehyde at room temperature and permeabilized at 37°C with 0.2% triton X-100, then blocked for 1 hour at room temperature with 5% goat serum albumin. The cells and/or tissues sections were incubated with primary antibodies at 4°C overnight, then washed three times with PBS, incubated with a second antibody at 37°C for 1 hour. Nuclei were revealed using DAPI staining. Fluorescence images were collected under a confocal microscope immediately. All of the immunofluorescence data were quantified using Image J software. Specifically, quantification of the target protein was based on five fields taken at random from each slide; nine slides for each group were examined. The area ratio between the target protein and cells or tissues in every field was calculated (with content color thresholds). The area ratio was then normalized to the control group.
Western blotting
Total proteins were extracted from cells or livers of CD1 mice using a commercial kit containing lysis buffer, protease inhibitors, phosphatase inhibitors, 100 mM PMSF. Protein concentrations were detected with a BCA protein assay kit. Protein samples were then mixed with sodium dodecyl sulfate loading buffer and boiled for 10 minutes. A 30-mg protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Following electrophoresis, proteins were transferred to a polyvinylidene difluoride membrane electronically. The membrane was blocked with 5% BSA for 1 hour at room temperature and incubated with a primary antibody overnight at 4°C. After incubation, the membrane was washed three times in Tris-buffered saline with Tween and followed by incubation with a horseradish peroxidase conjugated secondary antibody for 1 hour. The signals were detected using enhanced chemiluminescence reagents and visualized with the Vilber Fusion image system. Densitometry analysis was performed using Fusion software, and the expression of a target protein was normalized to b-actin level.
Analysis of lysosomal acidification
Cells were grown on glass coverslips and treated with BPA. After 24 hours of treatment, cells were cultured with acridine orange (AO; Sigma-Aldrich) at a concentration of 5 mg/mL at 37°C for 30 minutes. Immediately after three washes with PBS to remove excess AO, the cells were subjected to analysis under a confocal microscopy.
For double labeling, cells were fixed in 4% paraformaldehyde at room temperature and stained with Bodipy 493/503 at a concentration of 1 mg/mL at 37°C for 15 minutes. Thereafter, the stained cells were washed with PBS for three times, and subjected to a confocal microscope.
Transmission electron microscopy
HepG2 cells were fixed with 4% glutaraldehyde in 0.1 M sodium phosphate buffer (pH 7.4), digested with trypsin, washed with a buffer for three times at 4°C, and followed by postfixing with 1% osmium tetroxide. Thereafter, the cells were dehydrated using ethanol and stained with acetate uranyl overnight, then dehydrated using propane. The cells were then embedded in polyepoxide. Thin sections were cut and examined with an electron microscope.
Statistical analysis
Statistical analysis was performed using GraphPad PRISM software. Numeric data were expressed as means 6 standard error of the mean. Statistical significance of two groups was determined using Student t test. Data involving the combination of BPA and an autophagy inhibitor (EE or CQ) or enhancer (Torin1) were assessed using two-way analysis of variance. The statistical significance of differences was considered at values of P , 0.05.
Results
BPA increased hepatic lipid accumulation in hepatocytes
The effect of BPA on hepatic lipid accumulation was examined in cultured hepatocytes. Compared with control, treatment with BPA at low doses within the range of 0.001 and 4 mM did not elicit obvious changes on hepatocyte lipid accumulation. However, treatment with BPA at a dose of 10 mM caused an obvious increase in hepatocyte lipid 
BPA dysregulated autophagy in hepatocytes
BPA caused accumulation of autophagosomes
Due to a reverse correlation between autophagy and lipid content in hepatocytes (11) , it was expected that autophagy marker LC3 was downregulated in lipid accumulation models induced by BPA treatment. In the current study, this was the case. Specifically, the LC3 amount was obviously increased in BPA-treated HepG2 cells [ Fig. 2 (14) . As shown in Fig. 2(c) , BPA-treated HepG2 cells contained much more autophagosomes compared with control-treated cells, indicated by the results of transmission electron microscopy image analysis. In addition, colocalization of LC3 with Bodipy 493/503 was increased in BPA-treated HepG2 cells [ Fig. 2(f) ], which confirmed a direct interaction between autophagosomes and intracellular lipids.
BPA inhibited autophagic induction
Accumulated autophagosomes could result from enhanced induction of autophagy or inefficient completion of autophagy (e.g., decreased autophagic degradation) (15) . To investigate the mechanisms underlying the accumulation of autophagosomes caused by BPA, the effect of BPA on inducing autophagy was analyzed. As reported before, inhibition of mTOR signaling pathway is a well-recognized marker of autophagic induction (16) . In the current study, the levels of the phosphorylated mTOR, as well as its substrate p70S6 kinase were increased in BPA-treated HepG2 cells. mTOR suppression of autophagy involves in ULK1, whose phosphorylation at Ser757 is targeted by mTOR and contributes to inhibition of autophagy (17) . As shown in Fig. 3(a) , the phosphorylation of ULK1 at Ser757 was increased in BPA-treated HepG2 cells. Additionally, Atg5, another marker of autophagic induction, was suppressed upon BPA treatment in HepG2 cells [ Fig. 3(a) and 3(c) ].
BPA impaired autophagic degradation
Because enhanced induction of autophagy appeared to not account for the accumulated autophagosomes caused by BPA (18), we focused on examining the effect of BPA on autophagic degradation. P62 is an autophagyspecific substrate, and the accumulation of this protein is considered as a hallmark of impaired autophagic degradation. In the current study, accumulated p62 was found in the cytoplasm of HepG2 cells exposed to BPA, evidenced by immunofluorescence (Supplemental Fig. 2) . Consistently, the protein levels of p62 were increased in hepatocytes upon treatment with BPA [ Fig. 3(b) ]. These results indicate that BPA impaired autophagic degradation.
Because autophagy-induced degradation of macromolecules, including lipids, takes place mainly in lysosomes, we further focused on the effect of BPA on lysosomal function. Because acidification is required for activation of most lysosomal enzymes, the maintenance of acidity is a hallmark of normal functions of lysosomes (19) . The acidification of lysosomes in HepG2 cells was detected by assessing the cytoplasmic retention of AO. The nonprotonated monomeric form of AO emits green fluorescence in the cytosol. When AO enters acidic lysosomes, the protonated form becomes trapped in aggregates that fluoresce bright red (20) . In the current study, the cytoplasmic AO-red dots were dramatically decreased in HepG2 cells treated with BPA as compared with controls [ Fig. 4(a) ], indicating reduction of acidified compartments. To further investigate whether impaired acidification influenced the function of lysosomal enzymes, the current study showed that the expression of cathepsin L was decreased in BPA treated HepG2 cells [ Fig. 4(b) ].
Regulating autophagy altered lipid accumulation induced by BPA
Torin, an inhibitor of mTOR that can restore the autophagy flux, was used to determine whether autophagy dysregulation is directly involved in BPA-induced intracellular lipid accumulation. In the current study, Torin1 enhanced autophagic induction, demonstrated by an increase in LC3-II protein levels [ Fig. 5(a) ]. Restored autophagy by the mTOR inhibition was accompanied with an obvious decrease in BPA-mediated accumulation of intracellular lipids [ Fig. 5(d) ], strongly suggesting the involvement of autophagy in BPA-induced lipid deposition. In addition, two-factor statistics analysis revealed an interaction between BPA and Torin1 on TG content (P = 0.001).
As shown in Fig. 5 , BPA caused lysosomal inhibition and disrupted autophagy, similar to the effects of CQ and EE (a combination of E64d, NH 4 Cl, and pepstatin A). The latter are lysosomotropic compounds that elevate the lysosomal pH and inhibit degradation of autophagosome (21) . When combined with CQ or EE, treatment with BPA 
BPA increased hepatic lipid accumulation and dysregulated autophagy in livers of CD1 mice
The representative images in Fig. 6(a) illustrated an obvious accumulation of lipids in the liver of mice exposed to BPA compared with control. Consistently, liver levels of TGs were increased by ;58%, 69%, and 83% in mice exposed to BPA at different doses of 5, 50, and 500 mg/kg/d, respectively, compared with those in control mice [ Fig. 6(b) ]. In addition, the levels of LC3-II in the liver of mice exposed to BPA were increased [ Fig.  6 (c) and 6(g)], in accordance with the in vitro results. Compared with control, the levels of p-mTOR, p-p70S6 kinase, and p-ULK1 were increase and the levels of Atg5 were decreased in the liver of mice exposed to BPA [ Fig. 6(d) ]. Furthermore, accumulated p62 was found in the liver of mice exposed to BPA [ 
Discussion
The U.S. Food and Drug Administration states that according to their current perspective on BPA in food contact applications released in November 2014, it is considered to be safe within the current range of BPA exposure in foods (http://www.fda.gov/newsevents/ publichealthfocus/ucm064437.htm). However, the public health concern with BPA exposure still remains because new evidence keeps emerging and raises questions about the safety of BPA (22) (23) (24) (25) , and the U.S. Food and Drug Administration promises to continue their review on the available information and studies of BPA. The link between BPA and hepatic lipid deposition has been emphasized in several studies (5) (6) (7) (26) (27) (28) . Marmugi et al. (5) found that liver levels of TGs were increased by ;60% and 65% in mice exposed to 50 and/or 500 mg BPA/kg/d for 28 days, which was in line with our in vivo results. At the cellular level, Huc et al. (6) reported that BPA, at a concentration ) showed that BPA, at a concentration of 30 or 300 ng/mL (equivalent to 0.1 or 1 mM, respectively), increased intracellular TG content in rat FAO hepatoma cells. Consistent with these findings, we revealed that BPA, at a concentration of 10 mM, induced an increase in lipid accumulation in both HepG2 cells and primary hepatocytes; although BPA did not significantly alter hepatocyte lipid accumulation at a concentration between 0.1 and 1 mM.
To date, the mechanisms underlying BPA-induced hepatic lipid accumulation remain to be explored. According to accepted concepts, hepatic lipid accumulation is attributable to metabolic perturbations (e.g., increased fatty acids delivery to hepatocytes and TGs synthesis, decreased hepatic fatty acids oxidation, and/or inadequate TGs secretion). As supporting evidence, increased expression of genes related to lipid synthesis appeared to be involved in BPA-induced lipid accumulation (5) . In the study of Grasselli et al. (7), the effect of BPA on lipid homeostasis in FAO cells was shown to be associated with altered lipid oxidation and secretion, but not lipid synthesis, as indicated by the expression of fatty acid synthase. Recent studies have demonstrated autophagy as a crucial pathway of lipid metabolism. Additional to causing perturbations of classic fat metabolic pathways, BPA may cause dysregulation of autophagy, thereby contributing BPA-induced lipid accumulation. This was the case. Our current study reveals that BPA exerted important impacts on autophagy-regulated lipid metabolism, as this was evidenced by enhanced colocalization of autophagy marker LC3 with lipid droplets in BPA-treated HepG2 cells. Of significance, dysregulated autophagy in hepatocytes promotes BPA-induced hepatic lipid accumulation, which provides a novel insight into BPA actions on autophagy and nonalcoholic fatty liver disease. Currently, there are limited studies addressing the effect BPA on autophagy. For example, a recent study showed that LC3-II protein amount in pancreatic b-cells of rats was increased upon BPA treatment (50 mg/kg/d) for 35 weeks (29) . However, the authors did not investigate whether increased expression of LC3-II is due to enhanced induction of autophagy or inefficient autophagic degradation.
It is an interesting finding that BPA displayed suppressive effects on autophagic induction although BPA treatment caused increases in LC3 levels and in the accumulation of autophagosomes. In fact, LC3 and autophagosome are intermediate structures in a dynamic pathway, and their amount observed at any specific time point reflects the balance between the rates of their generation and degradation (30) . In other words, the appearance of more LC3 or autophagosomes does not necessarily indicate enhanced autophagy. In many cases, autophagosomes accumulate because of a block in trafficking to lysosomes or a reduction in degradative activity (15) . To further illustrate why BPA exposure increased LC3 and autophagosomes, the autophagic process was studied from different aspects. Our results validated that BPA inhibited both autophagic induction and autophagic degradation, and the imbalance between suppressed autophagic induction and inefficient completion of autophagy resulted in accumulated autophagosomes.
mTOR is an evolutionarily conserved serine/threonine protein kinase that plays a critical role in autophagy (31) . Enhanced mTOR activity negatively regulates autophagic induction through coordinated phosphorylation of ULK1 at Ser757 (17) . Previously, BPA was reported as a direct activator of mTOR signaling in yeast and mammalian cells (32) (33) (34) . In the current study, we found that the ability of BPA to activate mTOR activity, both in vitro and in vivo, is involved in inhibition of autophagy initiation. Singh et al. (11) demonstrates that knockdown of Atg5, a protein playing a critical role in autophagic induction, increased TG levels in hepatocytes. In our study, the suppressive effect of BPA on autophagic induction was also associated with inhibition of Atg5.
To better understand the effect of BPA on autophagy, several well-characterized autophagy inhibitors were used in our study. These inhibitors have been proven to be effective on suppressing autophagy (35) . For instance, CQ and EE are compounds frequently used to inhibit degradation of autophagosome. We showed that BPA treatment caused accumulation of LC3. This effect was similar to the effects of CQ and EE, suggesting that BPA inhibited autophagic degradation. Although changes in autophagy-lysosomal pathway were observed with BPA exposure, it remains unclear whether dysregulated autophagy is the culprit of BPA-induced lipid accumulation. Both inhibitors (CQ and EE) and inductor (Torin1) of autophagy were used to validate that the autophagy-lysosomal pathway is essential for the deposition of intracellular fat induced by BPA. In the presence of Torin1, restored autophagy flux decreased BPA-mediated accumulation of intracellular lipid. In contrast, in the presence of CQ or EE, further inhibited autophagy exacerbated the effect of BPA on inducing accumulation of intracellular lipid. It is noteworthy that LC3-II levels were increased in the presence of either autophagic inhibitors (CQ or EE) or inductor (Torin1), as compared with BPA alone. The underlying mechanisms, however, are quite different. Torin1 is a catalytic inhibitor that is able to suppress mTOR activity via binding to ATP-binding sites (36) . In the presence of Torin1, mTOR activity is inhibited and autophagy initiation is promoted; therefore, increased LC3-II levels are mainly due to enhanced formation of LC3-II. CQ or EE aggravates the inhibition of autophagosome degradation, and LC3-II accumulation is due to lessened degradation. In our study, a decreased tendency of TG was found in the rapamycin/BPA group as compared with the BPA group, although rapamycin did not significantly improve BPA-induced lipid accumulation (data not shown). The differences between Torin1 and rapamycin on BPA-induced TG accumulation might be attributable to the different potency of the two compounds. Torin1 is an mTOR catalytic inhibitor, whereas rapamycin is an allosteric inhibitor. Also, previous studies revealed that rapamycin is less potent than Torin1 (37-39). As such, the two mTOR inhibitors might exert different effects on BPA-induced autophagy disturbance.
In summary, this study demonstrated the involvement of the autophagy-lysosomal pathway as a novel mechanism in BPA-induced lipid accumulation. It appears that BPA has dual inhibitory effects on autophagy (e.g., suppressing the initiation of autophagy and inhibiting autophagic degradation). The imbalance between suppressed autophagic induction and inefficient completion of autophagy resulted in autophagosomes accumulation, which in turn contributed to BPA-induced hepatic lipid deposition (Fig. 7) . In addition, our study revealed that activation of mTOR activity is likely the major mechanism for the inhibition of autophagy initiation. However, how BPA inhibits autophagic degradation specifically needs to be studied further. Table   Peptide 
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